| Literature DB >> 19157502 |
Marta Mendiola1, Jorge Barriuso, Adrián Mariño-Enríquez, Andrés Redondo, Aurora Domínguez-Cáceres, Ginés Hernández-Cortés, Elia Pérez-Fernández, Iker Sánchez-Navarro, Juan Angel Fresno Vara, Asunción Suárez, Enrique Espinosa, Manuel González-Barón, José Palacios, David Hardisson.
Abstract
We investigated the expression of Aurora kinases A and B by immunohistochemistry in 68 ovarian carcinomas to analyze their prognostic value. The amplification of AURKA gene by fluorescence in situ hybridization was also assessed. Overall, 58.8% and 85.3% of ovarian carcinomas showed expression of Aurora A and B, respectively. Amplification of AURKA was found in 27.6% of cases examined. Tumors with Aurora A expression showed a lower rate of recurrence than those tumors without Aurora A expression (65% versus 91.7%, P = .019). In the univariate analysis, patients with Aurora A and B expression showed an increased progression-free survival (P = .023 and .06, respectively, log-rank test) and overall survival (P = .03 and .02, respectively, log-rank test). The multivariate analysis adjusted to optimal surgery by Cox proportional hazards regression showed Aurora A expression as an independent prognostic factor for progression-free survival (P = .03) and overall survival (P = .02). In conclusion, Aurora A expression seems to have a prognostic value in ovarian carcinoma.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19157502 DOI： 10.1016/j.humpath.2008.10.011
Source DB: PubMed Journal: Hum Pathol ISSN： 0046-8177 Impact factor: 3.466